CIK 0000887359 · Large accelerated filer
Vericel Corp
Sign in to watch- Ticker
- VCEL
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- MI
- Entity type
- operating
- EIN
- 943096597
- Phone
- 6175885555
- Business address
- 25 BLUE SKY DRIVE, BURLINGTON, MA, 01803
- Former names
- AASTROM BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,787,802
- in 7 filings, $5.8M under 10b5-1 plans
Net −$5,787,802. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Mara Joseph Anthony Jr −$4.1M Chief Financial Officer sold 82% of stake
- Flynn Sean C. −$779K Chief Legal Officer sold 88% of stake
- MCLAUGHLIN KEVIN F −$413K Director sold 28% of stake
- ZERBE ROBERT L MD −$386K Director sold 19% of stake
- SIEGAL JONATHAN −$79K Principal Accounting Officer sold 54% of stake
Reading 65 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-11-12 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $57.50 | $144K | 26,595 |
| 2024-11-12 | ZERBE ROBERT L MD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +2,500 | 12,500 | ||
| 2024-11-11 | ZERBE ROBERT L MD Director | Option exercise 10b5-1 | +2,500 | $13.05 | $33K | 29,095 |
| 2024-11-11 | ZERBE ROBERT L MD Director | Sale 10b5-1 | −2,500 | $55.00 | $138K | 26,595 |
| 2024-11-11 | ZERBE ROBERT L MD Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +2,500 | 15,000 | ||
| 2024-10-17 | Hagen Heidi Director | Option exercise | +4,000 | $3.74 | $15K | 22,650 |
| 2024-10-17 | Hagen Heidi Director | Option exercise | +6,000 | $3.74 | $22K | 28,650 |
| 2024-10-17 | Hagen Heidi Director | Option exercise · Stock Option (Right to Buy) | +4,000 | 0 | ||
| 2024-10-17 | Hagen Heidi Director | Option exercise · Stock Option (Right to Buy) | +6,000 | 9,000 | ||
| 2024-10-17 | Colangelo Dominick President and CEO | Option exercise 10b5-1 | +17,500 | $3.02 | $53K | 238,437 |
| 2024-10-17 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $40.34 | $706K | 220,937 |
| 2024-10-17 | Colangelo Dominick President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +17,500 | 35,000 | ||
| 2024-10-16 | Colangelo Dominick President and CEO | Option exercise 10b5-1 | +17,500 | $3.02 | $53K | 238,437 |
| 2024-10-16 | Colangelo Dominick President and CEO | Sale 10b5-1 | −17,500 | $41.38 | $724K | 220,937 |
| 2024-10-16 | Colangelo Dominick President and CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | +17,500 | 52,500 | ||
| 2024-10-16 | GILMAN STEVEN C Director | Option exercise 10b5-1 | +5,833 | $13.05 | $76K | 16,833 |
| 2024-10-16 | GILMAN STEVEN C Director | Sale 10b5-1 | −5,833 | $41.36 | $241K | 11,000 |
| 2024-10-16 | GILMAN STEVEN C Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | +5,833 | 0 | ||
| 2024-10-02 | GILMAN STEVEN C Director | Option exercise 10b5-1 | +5,833 | $13.05 | $76K | 16,833 |
| 2024-10-02 | GILMAN STEVEN C Director | Sale 10b5-1 | −5,833 | $40.35 | $235K | 11,000 |
Page 22 of 75 · 1,497 trades